3d systems and united therapeutics announce expansion of bioprinting program

Rock hill, s.c. and manchester, n.h., oct. 27, 2021 (globe newswire) -- 3d systems (nyse:ddd) is pleased to announce an expansion of its joint development program with united therapeutics corporation (nasdaq:uthr). the development and license agreement, first established in 2017, combines the 3d printing expertise of 3d systems, with the regenerative medicine and organ manufacturing expertise of united therapeutics (ut). to date, the program has had a strong, singular focus on developing the capability to print scaffolds for human lungs using a process we call print to perfusion™. this 3d printed scaffold would then be cellularized using cells derived from the recipient patient's own body, to create personalized human lungs. 3d systems has focused primarily on establishing the printing technology to produce scaffolds meeting the extreme precision and resolution requirements for a functional human lung and to do so in a manner that yields the physical, mechanical, and biocompatibility performance to influence cell behavior and reproduction required for extended use in the human body. the goal of the program is to establish an unlimited supply of human lungs, requiring no immunosuppression, allowing all patients with end-stage lung disease to receive transplants which will enable them to enjoy long and active lives. based upon the progress made toward this goal, the program is now being expanded to include two additional human organs, with support now designated through 2025.
DDD Ratings Summary
DDD Quant Ranking